Big Pharma Needs Smarter Regulations
President Trump spent a lot of time talking about prescription drug prices yesterday. While it’s a topic that hits home for just about everyone, there are big differences between the largess of health care insurers and drug makers.
Publicly traded giants in Big Pharma peaked long ago in the midst of the blockbuster drug craze, which brought in huge moneymakers, but resulted in thin pipelines and an avalanche of cheap generic alternatives thereafter.
Shares of the biggest names in pharmaceuticals have a long way to go to get back to their all-time highs, having peaked a long time ago.
The industry needs smarter regulations that will allow them longer shelf-life for patents and easier for competition. As for pricing vis-a-vis other nations, it just means the prices over there have to go higher. Last year, the top five selling prescription drugs saw limited pricing power and revenue increases, or in some cases, saw total sales decline.
Johnson & Johnson and Merck
Roche (Genentech) and Biogen
Indication(s): non-Hodgkin’s lymphoma; chronic lymphocytic leukemia
Amgen and Pfizer
Indication(s): Rheumatoid arthritis; polyarticular juvenile idiopathic
Sponsor(s): Gilead Sciences
Indication(s): indicated with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection
#1. Humira® (adalimumab)
Indication(s): moderate to severely active rheumatoid arthritis (RA
Add a Comment!
Products & Services |
In The Media |
About Us |
All Rights Reserved.